Clinical trials: Hepatitis; Epidemic
Hepatitis C
Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) + velpatasvir (VEL; GS-5816) with or without ribavirin (RBV) in treatment-naive adults with chronic…
- Trial name
- NCT01909804
- Testing
- SOF, VEL, RBV
- Where
- 49 sites in United States, Australia and 2 more
- Volunteers
- 323 people
- Sponsor
- Gilead Sciences
Hepatitis B, Chronic
A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)
This study is being done to compare the safety and efficacy of PEG-Intron™ to that of PEGASYS™ in participants with chronic hepatitis B (hepatitis B envelope antigen [HBeAg] positive or negative) who have not previously been…
- Trial name
- NCT01641926
- Testing
- PEG-Intron™, PEGASYS™
- Volunteers
- 402 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C
This study is a 24-week multicenter, randomized, double-blind control trial with ursodeoxycholic acid (UDCA) in patients with chronic hepatitis C in Japan.
- Trial name
- NCT00200343
- Testing
- Ursodeoxycholic acid 150mg / day, Ursodeoxycholic acid 600mg / day, Ursodeoxycholic acid 900mg / day
- Where
- Japan
- Volunteers
- 596 people
- Sponsor
- Tanabe Pharma Corporation
HEPATITIS C (HCV)
AI-Powered Hepatitis C Single-Encounter Test-and-Treat
This study will evaluate a single-visit approach to hepatitis C treatment in patients seen in the emergency department. Participants with hepatitis C will receive rapid testing and, if eligible, hepatitis C medication before…
- Trial name
- NCT07793643
- Testing
- Epclusa (sofosbuvir and velpatasvir)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Patrick Grace
Hepatitis B, Chronic
Clinical and Basic Research of ETV Plus GM-CSF in Chronic Hepatitis B Patients
Previous studies indicated that Granulocyte Macrophage-colony Stimulating Factor (GM-CSF) could improve survival rate in patients with acute liver failure and obtain higher HBsAg seroconversion rate when in combination with…
- Trial name
- NCT03164889
- Testing
- Granulocyte Macrophage-colony Stimulating Factor, Entecavir
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Beijing 302 Hospital
HCV Infection
A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C
The purpose of this study is to determine multiple dose safety, tolerability and pharmacokinetics of ABT-072 under nonfasting conditions in healthy adult subjects, and to determine the effect of single dose administration of…
- Trial name
- NCT00890318
- Testing
- ABT-072, ketoconazole
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Abbott
Hepatitis B
Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs
To evaluate the persistence of antibodies against hepatitis B at 30, 42, 54 and 66 months after the first dose of the hepatitis B primary vaccination course.
- Trial name
- NCT00343915
- Testing
- Engerix™-B (thiomersal-free) 20µg, 10 μg Engerix™-B (preservative-free)
- Where
- 4 sites in Australia, Belgium and 1 more
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B
HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers
Antibodies are the primary mediators of the protection against infection provided by vaccination. Antibodies become most powerful after the B cells that produce them undergo an evolutionary process called affinity maturation, in…
- Trial name
- NCT05272735
- Testing
- Hepatitis B Vaccine (Recombinant)
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Severe Alcoholic Hepatitis
Efficacy of G-CSF in the Management of Steroid Non-responsive Severe Alcoholic Hepatitis
After successful screening, first the investigators first treat patients of severe alcoholic hepatitis with steroids for 7 days.
- Trial name
- NCT01820208
- Testing
- G-CSF
- Where
- India
- Volunteers
- 28 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Chronic Hepatitis c
'Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat'
Objective: To coordinate active tracing of chronic hepatitis C patients lost to follow-up to inform them about there disease severity and treatment options.
- Trial name
- Track&Trace (NCT03088917)
- Where
- Netherlands
- Volunteers
- 106 people
- Sponsor
- Radboud University Medical Center
HIV Infection and Chronic Alanine Aminotransferase Elevation
Prevalence of Liver Fibrosis and Progression of Liver Fibrosis
Little is known about the clinical significance of chronic alanine aminotransferase (ALT) elevation in HIV-infected patients without hepatitis B and C coinfection.
- Trial name
- NCT01208376
- Testing
- Fibroscan
- Where
- Switzerland
- Volunteers
- 195 people
- Sponsor
- Helen Kovari-Kramer
Beta Thalassemia Major
Effect of Spirulina on Serum Hyaluronic Acid in Beta Thalassemic Children With Hepatitis C
Thalassemics can develop liver fibrosis because of iron overload and hepatitis C infection. The latter is the main risk factor for liver fibrosis in transfusion dependent thalassemics.
- Trial name
- NCT02744547
- Testing
- Spirulina
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Chronic Hepatitis b
Therapeutic Effects and Long-term Follow-up After Ending Nucleos(t)Ide Analogs Therapy in Chronic Hepatitis b
The study is to observe the therapeutic effects and long-term follow-up after ending anti-HBV therapy with nucleos(t)ide analogs in patients with chronic hepatitis b.
- Trial name
- NCT02883647
- Testing
- Entecavir or Tenofovir
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatic Fibrosis
Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium
When someone has hepatitis C or some other condition that causes liver injury, he or she can develop a condition called liver fibrosis that over time, can cause the liver to stop working normally.
- Trial name
- NCT01783314
- Testing
- MRI of liver
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Hepatitis C
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
The investigators will conduct a randomized controlled clinical trial study in an urban emergency department in Baltimore to determine the impact of an educational app which is based on Leventhal's Common-Sense Model of Illness…
- Trial name
- NCT04162938
- Testing
- Patient-Centered Electronic App
- Where
- United States
- Volunteers
- 308 people
- Sponsor
- Johns Hopkins University
Hepatitis B, Liver Cirrhosis
Entecavir for Decompensated HBV Cirrhosis
Entecavir (ETV) and tenofovir (TDF) are the first-line drugs for treatment of chronic hepatitis B virus (HBV) infection. Chronic HBV infection gradually progress to liver cirrhosis.
- Trial name
- NCT03345498
- Testing
- Entecavir
- Where
- India
- Volunteers
- 32 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Hepatitis B, Chronic
A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B
This study is divided into two parts. Phase Ib is a randomized, double-blind, placebo-controlled trial, designed to evaluate the safety, tolerability, pharmacokinetic characteristics, preliminary efficacy, and immunogenicity of…
- Trial name
- NCT06452693
- Testing
- Nucleotide drugs Control group
- Where
- 22 sites in China
- Volunteers
- 162 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NASH - Nonalcoholic Steatohepatitis
Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients
Multicenter, open-label, safety and tolerability study of ascending doses of HepaStem in patients with cirrhotic and pre-cirrhotic non-alcoholic steato-hepatitis (NASH) to determine the safety and tolerability of ascending single…
- Trial name
- PANASH (NCT03963921)
- Testing
- HepaStem
- Where
- 13 sites in Belgium, Bulgaria and 2 more
- Volunteers
- 23 people
- Sponsor
- Cellaion SA
Kidney Failure, Chronic, Hepatitis C
Safety of Sofosbuvir in People With Advanced Kidney Failure
Infection with hepatitis C virus (HCV), a hepatotropic RNA virus, is often chronic, and causes liver cirrhosis and liver cancer. The virus is transmitted through parenteral exposure.
- Trial name
- NCT03883698
- Testing
- Sofosbuvir, Daclatasvir 60 mg
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Primary Bilary Cirrhosis (PBC), Autoimmune Hepatitis
Canadian Network for Autoimmune Liver Disease
CaNAL is a longitudinal observational cohort study of patients diagnosed with Primary Biliary Cholangitis (PBC), Autoimmune Hepatitis (AIH), or overlap syndrome.
- Conditions
- Primary Bilary Cirrhosis (PBC), Autoimmune Hepatitis, Overlap Syndrome
- Trial name
- CaNAL (NCT03569826)
- Testing
- Observational; no intervention
- Where
- 15 sites in Canada
- Volunteers
- 2,500 people
- Sponsor
- University Health Network, Toronto
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.